[{"name":"TARGET","title":"","children":[{"id":"AMHRII","name":"AMHRII","presenterLast":"AMHRII","children":[{"id":2593,"name":2593,"title":"Anti-M\u00fcllerian hormone type II receptor (AMHRII), a cancer target for GM103, a novel antibody-drug conjugate (ADC)","presenterFirst":"Jean-Marc","presenterLast":"Barret","keywords":"Targeted drug delivery;Antibody Drug Conjugate;AMHRII;Antitumor agents","target":"AMHRII","tumor":"ovary_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"ASCT2","name":"ASCT2","presenterLast":"ASCT2","children":[{"id":10651,"name":10651,"title":"MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent <i>in vivo</i> activity across a spectrum of hematological malignancies","presenterFirst":"Noel","presenterLast":"Monks","keywords":"Targeted drug delivery;Antibody;Pyrrolobenzodiazepines;Animal models","target":"ASCT2","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":10662,"name":10662,"title":"Discovery and development of MEDI7247, a novel Pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological and solid cancers","presenterFirst":"Nabendu","presenterLast":"Pore","keywords":"Pyrrolobenzodiazepines;Antibody;Solid tumors;Multiple myeloma","target":"ASCT2","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10703,"name":10703,"title":"MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors","presenterFirst":"Kevin","presenterLast":"Schifferli","keywords":"Targeted drug delivery;Antibody;Solid tumors;Pyrrolobenzodiazepines","target":"ASCT2","tumor":"lung_colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"AXL","name":"AXL","presenterLast":"AXL","children":[{"id":3239,"name":3239,"title":"Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors","presenterFirst":"Francesca","presenterLast":"Zammarchi","keywords":"Targeted drug delivery;Cancer","target":"AXL","tumor":"tnbc_renal_pancreas","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3284,"name":3284,"title":"Development of novel formats of anti-AXL ADCs","presenterFirst":"Maria","presenterLast":"Jaramillo","keywords":"Antibody;Axl;antibody drug conjugate (ADC);Targeted drug delivery","target":"AXL","tumor":"breast_ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6172,"name":6172,"title":"An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC","presenterFirst":"Louise","presenterLast":"Koopman","keywords":"Non-small cell lung cancer;AXL;EGFR tyrosine kinase inhibitor resistance;antibody-drug conjugate","target":"AXL","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6710,"name":6710,"title":"Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC","presenterFirst":"Leslie","presenterLast":"Sharp","keywords":"Antitumor agents;Antibody;antibody drug conjugate;Axl","target":"AXL","tumor":"lung_prostate_pancreatic","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"B7-H3","name":"B7-H3","presenterLast":"B7-H3","children":[{"id":3067,"name":3067,"title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","presenterFirst":"Juniper","presenterLast":"Scribner","keywords":"Antibody;Targeted drug delivery;ADC;duocarmycin","target":"B7-H3","tumor":"breast_ovary_lung_melanoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6866,"name":6866,"title":"B7-H3 is a potential antibody drug conjugate target for the treatment of prostate cancer","presenterFirst":"Gareth","presenterLast":"Davies","keywords":"Anticancer therapy;Prostate cancer","target":"B7-H3","tumor":"prostate","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"CAIX","name":"CAIX","presenterLast":"CAIX","children":[{"id":3971,"name":3971,"title":"Head-to-head comparison of ADC and SMDC products, alone and in combination with antibody-IL2 fusion proteins","presenterFirst":"Samuele","presenterLast":"Cazzamalli","keywords":"Combination studies;Tumor Targeting;Targeted Cytotoxics;Immunocytokines","target":"CAIX","tumor":"renal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CD123","name":"CD123","presenterLast":"CD123","children":[{"id":5462,"name":5462,"title":"Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)","presenterFirst":"Yoon-Chi","presenterLast":"Han","keywords":"Antibody Engineering;Drug delivery;Anticancer therapy","target":"CD123","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"CD22","name":"CD22","presenterLast":"CD22","children":[{"id":6848,"name":6848,"title":"TRPH-222, a novel anti-CD22 antibody drug conjugate (ADC), has significant anti-tumor activity in NHL xenografts and reduces B cells in monkeys","presenterFirst":"Ann","presenterLast":"Maclaren","keywords":"Non-Hodgkin's lymphoma;B cells;Antibody;Anticancer therapy","target":"CD22","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"CD30","name":"CD30","presenterLast":"CD30","children":[{"id":5472,"name":5472,"title":"Novel auristatins with high activity on efflux-positive models and demonstrable bystander activity","presenterFirst":"Philip","presenterLast":"Moquist","keywords":"Antitumor agents","target":"CD30","tumor":"lymphoma","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5588,"name":5588,"title":"CD30<sup>+</sup>T regulatory cells, but not CD30<sup>+</sup>CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo","presenterFirst":"Ryan","presenterLast":"Heiser","keywords":"Regulatory T cells;Targeted drug delivery;Tumor immunity;Cytotoxic T lymphocytes","target":"CD30","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"CD33","name":"CD33","presenterLast":"CD33","children":[{"id":5865,"name":5865,"title":"Synergistic antileukemic activity of the antibody-drug conjugate (IMGN779) combined with PARP inhibition in preclinical human acute myeloid leukemia models","presenterFirst":"Eunice","presenterLast":"Wang","keywords":"PARP;Antibody;Leukemias: acute myeloid;DNA damage response","target":"CD33","tumor":"leukemia","sage":"target-tumor","pharma":"academia","combo":"yes","model":"preclinical in vitro"}]},{"id":"CD37","name":"CD37","presenterLast":"CD37","children":[{"id":6013,"name":6013,"title":"Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL)","presenterFirst":"Francesco","presenterLast":"Bertoni","keywords":"Lymphoma: non-Hodgkin's lymphoma;Anticancer therapy;Resistance;Targeted therapy","target":"CD37","tumor":"lymphoma","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"CD48","name":"CD48","presenterLast":"CD48","children":[{"id":886,"name":886,"title":"Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab","presenterFirst":"Timothy","presenterLast":"Lewis","keywords":"Antibody;Drug delivery;Microtubule-interfering agents;Multiple myeloma","target":"CD48","tumor":"myeloma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CD74","name":"CD74","presenterLast":"CD74","children":[{"id":6814,"name":6814,"title":"Nonclinical safety evaluation of STRO-001, a site-specific anti-CD74 antibody-drug conjugate for the potential treatment of B-cell malignancies","presenterFirst":"Willy","presenterLast":"Solis","keywords":"Anticancer therapy;Non-Hodgkin's lymphoma;Multiple myeloma;Toxicity","target":"CD74","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"CD79b","name":"CD79b","presenterLast":"CD79b","children":[{"id":3562,"name":3562,"title":"Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1","presenterFirst":"Dhara","presenterLast":"Amin","keywords":"Bcl-2 protein family;venetoclax;Lymphoma: non-Hodgkin's lymphoma;antibody drug conjugates","target":"CD79b","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"DLK-1","name":"DLK-1","presenterLast":"DLK-1","children":[{"id":3267,"name":3267,"title":"ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors","presenterFirst":"Francesca","presenterLast":"Zammarchi","keywords":"Targeted drug delivery;Tumor targeting","target":"DLK-1","tumor":"neuroblastoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"DLL3","name":"DLL3","presenterLast":"DLL3","children":[{"id":4031,"name":4031,"title":"Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer","presenterFirst":"Loredana","presenterLast":"Puca","keywords":"Targeted therapy;Neuroendocrine prostate cancer","target":"DLL3","tumor":"prostate","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":10711,"name":10711,"title":"<b></b>Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma","presenterFirst":"Renata","presenterLast":"Sano","keywords":"Immunotherapy;neuroblastoma;Rova-T;DLL3","target":"DLL3","tumor":"neruoblastoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"EGFR","name":"EGFR","presenterLast":"EGFR","children":[{"id":7656,"name":7656,"title":"ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma <i>in vivo</i>","presenterFirst":"Puey Ling","presenterLast":"Chia","keywords":"Antibody;Novel anticancer agents;In vivo;Mesothelioma","target":"EGFR","tumor":"mesothelioma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"endoglin","name":"endoglin","presenterLast":"endoglin","children":[{"id":4350,"name":4350,"title":"Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates","presenterFirst":"Rui","presenterLast":"Wu","keywords":"Vascular targeting;anti-endoglin ADC;Antitumor effect","target":"endoglin","tumor":"ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"Epha2","name":"Epha2","presenterLast":"Epha2","children":[{"id":5947,"name":5947,"title":"Targeting the EphA2-ligand binding domain for the design of innovative cancer therapeutics","presenterFirst":"Parima","presenterLast":"Udompholkul","keywords":"EphA2;Therapeutics;Peptidomimetics;Cancer","target":"Epha2","tumor":"prostate_pancreas_melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6609,"name":6609,"title":"Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528","presenterFirst":"Gavin","presenterLast":"Bennett","keywords":"EphA2;Drug discovery;Targeted drug delivery;Tumor targeting","target":"Epha2","tumor":"sarcoma_breast_lung","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"FGFR4","name":"FGFR4","presenterLast":"FGFR4","children":[{"id":6245,"name":6245,"title":"Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma","presenterFirst":"Adam","presenterLast":"Cheuk","keywords":"Antibody;Fibroblast growth factor receptor 4;Rhabdomyosarcoma;Anticancer therapy","target":"FGFR4","tumor":"sarcoma_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"Fn14","name":"Fn14","presenterLast":"Fn14","children":[{"id":7048,"name":7048,"title":"Molecular mechanistic and <i>in vivo</i> <i></i>efficacy studies of Fn14-targeted fusion constructs containing human granzyme B","presenterFirst":"Ana","presenterLast":"Alvarez de Cienfuegos","keywords":"Immunotherapy;Apoptosis;Granzyme B;Fn14","target":"Fn14","tumor":"lung_breast","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"FRA","name":"FRA","presenterLast":"FRA","children":[{"id":717,"name":717,"title":"MORAb-202, a folate receptor-alpha (FRA)-targeting antibody-eribulin drug conjugate (ADC), exhibits durable antitumor activity and payload-mediated bystander effects on the tumor microenvironment in triple-negative breast cancer","presenterFirst":"Keiji","presenterLast":"Furuuchi","keywords":"Antibody;Drug delivery;Triple negative breast cancer;Tumor microenvironment","target":"FRA","tumor":"tnbc","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":842,"name":842,"title":"Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer","presenterFirst":"Venita","presenterLast":"De Almeida","keywords":"Ovarian cancer;Folate Receptor Alpha;Antibody Drug Conjugate;Hemiasterlin","target":"FRA","tumor":"ovary","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3278,"name":3278,"title":"A new class of DNA alkylating indolino-benzodiazepine agents (BIAs) linked with a DNA binding moiety for use with antibody-drug conjugates (ADCs)","presenterFirst":"Michael","presenterLast":"Miller","keywords":"DNA;Drug delivery;Antibody;Cancer","target":"FRA","tumor":"NA","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4652,"name":4652,"title":"Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors","presenterFirst":"Caroline","presenterLast":"Mignard","keywords":"Antibody Engineering;Prognostic markers;Folate Receptor;Breast","target":"FRA","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5062,"name":5062,"title":"Development of an in vivo model system to assess the interplay between the various drivers of antibody-drug conjugate (ADC) activity","presenterFirst":"Leanne","presenterLast":"Lanieri","keywords":"Mouse models;Drug delivery;Antibody;Cancer","target":"FRA","tumor":"NA","sage":"other","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"GCC","name":"GCC","presenterLast":"GCC","children":[{"id":4797,"name":4797,"title":"Relationship of guanylyl cyclase C (GCC) expression and efficacy of TAK-164, a GCC-targeted antibody-drug conjugate in a panel of 68 subcutaneous HuPrime colorectal cancer PDX models","presenterFirst":"Erik","presenterLast":"Koenig","keywords":"Targeted therapy;GI Malignancies;antibody drug conjugate;Biomarker","target":"GCC","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"GFRA1","name":"GFRA1","presenterLast":"GFRA1","children":[{"id":2212,"name":2212,"title":"Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer","presenterFirst":"Emily","presenterLast":"Bosco","keywords":"Antibody;Breast cancer;Preclinical;Therapeutics","target":"GFRA1","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"Globo-H","name":"Globo-H","presenterLast":"Globo-H","children":[{"id":4413,"name":4413,"title":"Development of anti-Globo H ADC against cancer","presenterFirst":"Wei-Ting","presenterLast":"Sun","keywords":"Cancer;antibody drug conjugation;globo H","target":"Globo-H","tumor":"ovary_hcc","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"GPC1","name":"GPC1","presenterLast":"GPC1","children":[{"id":531,"name":531,"title":"Antibody-drug conjugate targeting glypican-1 shows potent antitumor effect in pancreatic cancer","presenterFirst":"Satoshi","presenterLast":"Serada","keywords":"Pancreatic cancer;Antibody;Drug delivery","target":"GPC1","tumor":"pancreas","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"GPC2","name":"GPC2","presenterLast":"GPC2","children":[{"id":3963,"name":3963,"title":"The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts","presenterFirst":"Kristopher","presenterLast":"Bosse","keywords":"Neuroblastoma;Antibody-drug conjugate;Pyrrolobenzodiazepines;Glypican 2","target":"GPC2","tumor":"neuroblastoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"HER2","name":"HER2","presenterLast":"HER2","children":[{"id":1983,"name":1983,"title":"Antibody-drug conjugates with DNA inhibitor linker-payloads can overcome resistance in cultured tumor cells made resistant to conjugates with cleavable-linked auristatins","presenterFirst":"Frank","presenterLast":"Loganzo","keywords":"Resistance;HER-2","target":"HER2","tumor":"gastric","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":3526,"name":3526,"title":"NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial","presenterFirst":"Matthew","presenterLast":"Sung","keywords":"HER-2;Preclinical testing;Targeted drug delivery;Xenografts","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4609,"name":4609,"title":"Thienoindoles: New highly promising agents for antibody-drug conjugates generation","presenterFirst":"Michele","presenterLast":"Caruso","keywords":"Antibody;Antitumor activity;Thienoindoles;ADC","target":"HER2","tumor":"breast","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5486,"name":5486,"title":"Unique pharmacologic properties of Dolaflexin-based ADCs\u2014a controlled bystander effect","presenterFirst":"Susan","presenterLast":"Clardy","keywords":"Bystander effect;Toxicity;Polymer drug conjugate","target":"HER2","tumor":"breast","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5678,"name":5678,"title":"ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers","presenterFirst":"Kevin","presenterLast":"Hamblett","keywords":"HER-2;Antibody drug conjugate;Bispecific antibody","target":"HER2","tumor":"breast_gastric","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5975,"name":5975,"title":"Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells","presenterFirst":"Wan-Chen","presenterLast":"Wei","keywords":"Breast cancer;HER-2;Metformin;T-DM1","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"yes","model":"preclinical xeno"},{"id":6317,"name":6317,"title":"FGFR signaling facilitates recurrence of minimal residual disease post trastuzumab emtansine treatment in breast cancer","presenterFirst":"Saeed Salehin","presenterLast":"Akhand","keywords":"Drug resistance;Recurrence;Tyrosine kinase inhibitor;Targeted therapy","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6326,"name":6326,"title":"CovisoLinK: New bacterial transglutaminase Q-Tag substrate for the development of site specific antibody-drug conjugates","presenterFirst":"Sandrine","presenterLast":"Valsesia-Wittmann","keywords":"Antibody Engineering","target":"HER2","tumor":"breast","sage":"linker","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6471,"name":6471,"title":"Structure-activity relationship studies and biological evaluation of novel maytansinoids, a class of highly selective tubulin inhibitors","presenterFirst":"Friederike","presenterLast":"Nollmann","keywords":"Solid tumors;Maytansine;SAR;Tubulin inhibitor","target":"HER2","tumor":"breast","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":6484,"name":6484,"title":"Development of next-generation antibody-drug conjugates for resistant HER2-positive tumors","presenterFirst":"Vincent","presenterLast":"Lacasse","keywords":"Cancer therapy;HER-2;Antibody-drug conjugate;Drug delivery","target":"HER2","tumor":"breast","sage":"resistance","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6575,"name":6575,"title":"Novel albumin-binding maytansinoids inducing long-term partial and complete tumor regressions in several human cancer xenograft models in nude mice","presenterFirst":"Friederike","presenterLast":"Nollmann","keywords":"Drug delivery;Xenograft;Kadcyla(R);Albumin","target":"HER2","tumor":"breast","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":7297,"name":7297,"title":"Characterizing antibody-drug conjugate cytotoxicity using four different real-time assays","presenterFirst":"Andrew","presenterLast":"Niles","keywords":"Antibody;Anticancer therapy;Apoptosis;Antiproliferative","target":"HER2","tumor":"breast","sage":"other","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":7696,"name":7696,"title":"Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window","presenterFirst":"Rupert","presenterLast":"Davies","keywords":"Bispecific antibody;Antibody drug conjugate","target":"HER2","tumor":"NA","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":8204,"name":8204,"title":"\u03b1<sub>3</sub>\u03b2<sub>1</sub>-Integrin targeted DM1 micellar prodrug for targeted therapy against ovarian cancer","presenterFirst":"Xiaocen","presenterLast":"Li","keywords":"Gynecological cancers: ovarian;DM1;micellar prodrug;drug delivery","target":"HER2","tumor":"ovary","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":9288,"name":9288,"title":"Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer","presenterFirst":"Ricarda","presenterLast":"Hoffmann","keywords":"Breast cancer;Antibody-drug conjugate;Trastuzumab;Ribosome-inhibitor","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":10616,"name":10616,"title":"Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2","presenterFirst":"Tary","presenterLast":"Traore","keywords":"HER-2;Cancer immunotherapy;Checkpoint;XMT-1522","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10689,"name":10689,"title":"HER2-targeted antibody drug conjugates induce host immunity and target cancer stem cells and the efficacy can be enhanced by anti-PD-L1","presenterFirst":"Qiao","presenterLast":"Li","keywords":"Cancer stem cell;antibody drug conjugate;anti-PD-L1;TILs","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"HER2_ROR1","name":"HER2_ROR1","presenterLast":"HER2_ROR1","children":[{"id":6193,"name":6193,"title":"Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies","presenterFirst":"Ulf","presenterLast":"Grawunder","keywords":"Antibody;Antitumor agents;Animal models;Anthracycline","target":"HER2_ROR1","tumor":"multiple","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"HER3","name":"HER3","presenterLast":"HER3","children":[{"id":4603,"name":4603,"title":"Targeting trastuzumab and T-DM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3","presenterFirst":"Gianluca","presenterLast":"Sala","keywords":"Resistance;HER-3/ErbB-3;Antibody-Drug Conjugate;HER-2+ breast cancer","target":"HER3","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"HSP90","name":"HSP90","presenterLast":"HSP90","children":[{"id":6760,"name":6760,"title":"Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy","presenterFirst":"Samantha","presenterLast":"Perino","keywords":"PARP;Combination studies;topoisomerase I inhibitor","target":"HSP90","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"IGF-1R","name":"IGF-1R","presenterLast":"IGF-1R","children":[{"id":3767,"name":3767,"title":"New approach for old target: W0101 antibody drug conjugate effectively inhibits tumor growth in preclinical models of IGF-1R overexpressing solid tumors","presenterFirst":"Barbara","presenterLast":"Akla","keywords":"Insulin-like growth factor 1 receptor;Antibody drug conjugate;Tumor growth inhibition;Novel anticancer agents","target":"IGF-1R","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"IL7R","name":"IL7R","presenterLast":"IL7R","children":[{"id":753,"name":753,"title":"IL-7R targeting therapy for immunoregulation and overcoming steroid resistance in cancer and autoimmune disease","presenterFirst":"Masahiro","presenterLast":"Yasunaga","keywords":"Antibody;Leukemia;Lymphoma;Steroid hormones","target":"IL7R","tumor":"autoimmune","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"LGALS3BP","name":"LGALS3BP","presenterLast":"LGALS3BP","children":[{"id":4537,"name":4537,"title":"Non-internalizing site-specific antibody-drug conjugates based on maytansinoids display curative properties","presenterFirst":"Emily","presenterLast":"Capone","keywords":"Antibody Engineering;Targeted drug delivery;LGALS3BP;non-internalizing ADC","target":"LGALS3BP","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"LIV-1","name":"LIV-1","presenterLast":"LIV-1","children":[{"id":5168,"name":5168,"title":"Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor","presenterFirst":"Anthony","presenterLast":"Cao","keywords":"Immunostimulation;Antibody;Breast cancer;Tumor microenvironment","target":"LIV-1","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"LRRC15","name":"LRRC15","presenterLast":"LRRC15","children":[{"id":5600,"name":5600,"title":"LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085","presenterFirst":"Eytan","presenterLast":"Ben-Ami","keywords":"Targeted drug delivery;Sarcoma/soft-tissue malignancies;Osteosarcoma;Target discovery","target":"LRRC15","tumor":"sarcoma","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"multiple","name":"multiple","presenterLast":"multiple","children":[{"id":608,"name":608,"title":"Comprehensive evaluation of antibody-drug conjugate targets for drug development across tumor types: Analysis from TCGA","presenterFirst":"Roman","presenterLast":"Groisberg","keywords":"Drug discovery;RNA;Gene expression profiling;Gene expression analysis","target":"multiple","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"NA","name":"NA","presenterLast":"NA","children":[{"id":1991,"name":1991,"title":"Antibody-drug conjugate payloads induce markers of immunogenic cell death in cancer cells","presenterFirst":"Frank","presenterLast":"Loganzo","keywords":"Immunomodulation;Doxorubicin;DNA double-strand break;Antibody","target":"NA","tumor":"multiple","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":4123,"name":4123,"title":"The lysosomal transporter SLC46A3 is a potential predictive biomarker for antibody-drug conjugates bearing the non-cleavable warheads SG3376 and DM1","presenterFirst":"Krista","presenterLast":"Kinneer","keywords":"Multiple myeloma;Antibody drug conjugate;BCMA;SLC46A3","target":"NA","tumor":"myeloma","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":4311,"name":4311,"title":"Synthesis and evaluation of sugar alcohol based molecules for drug conjugation and delivery","presenterFirst":"Yumei","presenterLast":"Huang","keywords":"Drug delivery;Polyethylene glycol;Antibody Drug Conjugate;Hydrophilic linker","target":"NA","tumor":"NA","sage":"linker","pharma":"academia","combo":"no","model":"in silico"},{"id":5268,"name":5268,"title":"Impact of linker and conjugation site on tubulysin M ADC stability and in vivo activity","presenterFirst":"Patrick","presenterLast":"Burke","keywords":"Antibody;Targeted drug delivery;Microtubule-interfering agents;Drug design","target":"NA","tumor":"NA","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5367,"name":5367,"title":"Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates","presenterFirst":"Christopher","presenterLast":"Neumann","keywords":"Antibody;Drug delivery;Metabolism;Antitumor activity","target":"NA","tumor":"multiple","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6076,"name":6076,"title":"A controlled affinity-guided ADC-linker (MAGNET) technology","presenterFirst":"Nimish","presenterLast":"Gupta","keywords":"Antibody;Targeted drug delivery","target":"NA","tumor":"lung","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":6140,"name":6140,"title":"Decomposition of parameters contributing to the improved therapeutic index of ADCs obtained by GlycoConnect\u2122 and HydraSpace\u2122 Technologies","presenterFirst":"Floris","presenterLast":"van Delft","keywords":"Immunotherapy;antibody-drug conjugates;linker;therapeutic index","target":"NA","tumor":"NA","sage":"linker","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6250,"name":6250,"title":"Development of an HPLC method for the assessment of hydrophobicity of ADC payloads","presenterFirst":"Ilona","presenterLast":"Pysz","keywords":"Antibody;Drug Congugate;Payload Hydrophobicity;HPLC Assay","target":"NA","tumor":"NA","sage":"payload","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6254,"name":6254,"title":"Superior efficacy of novel albumin-binding auristatin E-based prodrugs compared to auristatin E in a panel of human xenograft models in mice","presenterFirst":"Stephan","presenterLast":"Koester","keywords":"Drug delivery;Antitumor agents;Xenografts;Prodrugs","target":"NA","tumor":"multiple","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6608,"name":6608,"title":"Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity","presenterFirst":"Nicolas","presenterLast":"Veillard","keywords":"Antibody;Antibody-Drug Conjugate;Payload;DNA alkylating agents","target":"NA","tumor":"multiple","sage":"payload","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6765,"name":6765,"title":"Identifying an optimal site for linker conjugation of the taccalonolides, novel microtubule stabilizing drugs","presenterFirst":"April","presenterLast":"Risinger","keywords":"Tubulin;Drug resistance;Microtubule-interfering agents;Natural product","target":"NA","tumor":"NA","sage":"payload","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":6771,"name":6771,"title":"Modular coiled-coil masking domains for tumor-specific antibody activation","presenterFirst":"Vivian","presenterLast":"Trang","keywords":"Antibody Engineering;Prodrugs;Masked Antibodies;Tumor microenvironment","target":"NA","tumor":"NA","sage":"other","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":6941,"name":6941,"title":"Computational exploration of mechanistic determinants of ADC pharmacokinetics using QSP modeling strategies","presenterFirst":"John","presenterLast":"Burke","keywords":"Systems biology;Antibody;Pharmacokinetics","target":"NA","tumor":"NA","sage":"other","pharma":"pharma","combo":"no","model":"in silico"}]},{"id":"NKA","name":"NKA","presenterLast":"NKA","children":[{"id":6500,"name":6500,"title":"ADCs that induce necrosis and thwart apoptotic resistance","presenterFirst":"James","presenterLast":"Prudent","keywords":"Cancer therapy;Cell death;Immunotoxin;Chemoresistance","target":"NKA","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"OX001L","name":"OX001L","presenterLast":"OX001L","children":[{"id":3918,"name":3918,"title":"Preclinical development of a novel antibody-drug conjugate targeting \u201ccold\u201d tumors","presenterFirst":"Robert","presenterLast":"Boyd","keywords":"Therapeutics;Immunotherapy;Antibody;Immunotherapy","target":"OX001L","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"PD-L1","name":"PD-L1","presenterLast":"PD-L1","children":[{"id":4020,"name":4020,"title":"PD-L1 antibody drug conjugate for cancer immune-chemo combination therapy","presenterFirst":"Samaresh","presenterLast":"Sau","keywords":"Checkpoint;Antibody;Imaging;Immunotherapy","target":"PD-L1","tumor":"tnbc_lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"PSMA","name":"PSMA","presenterLast":"PSMA","children":[{"id":4532,"name":4532,"title":"Preclinical evaluation of an anti-PSMA antibody-targeted amanitin conjugate (ATAC)","presenterFirst":"Michael","presenterLast":"Kulke","keywords":"Antibody;Amanitin;Antibody drug conjugate;PSMA","target":"PSMA","tumor":"prostate","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"RON","name":"RON","presenterLast":"RON","children":[{"id":7284,"name":7284,"title":"Development of a novel ron receptor targeted antibody-drug conjugates using cysteine bridging technology for potential treatment of pancreatic cancer","presenterFirst":"Sreedhar Reddy","presenterLast":"Suthe","keywords":"Antibody;Immunotherapy;RON;Pancreatic cancer","target":"RON","tumor":"pancreas","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"ROR2","name":"ROR2","presenterLast":"ROR2","children":[{"id":6902,"name":6902,"title":"Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC","presenterFirst":"William","presenterLast":"Boyle","keywords":"Anticancer therapy;Antibody;antibody drug conjugate;Ror2","target":"ROR2","tumor":"lung_breast_sarcoma_melanoma","sage":"other","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"STn","name":"STn","presenterLast":"STn","children":[{"id":6892,"name":6892,"title":"Myeloid derived suppressor cells (MDSCs) express Sialyl Tn (STn) and are a therapeutic target for anti-STn antibody drug conjugates","presenterFirst":"David","presenterLast":"Eavarone","keywords":"Target discovery;Sialyl Tn (STn);Myeloid Derived Suppressor Cells;Therapeutic Antibody","target":"STn","tumor":"ovary","sage":"other","pharma":"pharma","combo":"no","model":"preclinical xeno"}]}]}]
